Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Anaemia Drugs Market Overview – 8 Major Markets
3.1 Anaemia Drugs Market Historical Value (2019-2025)
3.2 Anaemia Drugs Market Forecast Value (2026-2035)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Anaemia Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Anaemia Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2019-2035)
7.2 Prevalence of Anaemia, by Country
7.2.1 United States
7.2.2 United Kingdom
7.2.3 Germany
7.2.4 France
7.2.5 Italy
7.2.6 Spain
7.2.7 India
7.2.8 Japan
7.3 Total Diagnosed Cases of Anaemia, by Country
7.4 Gender-specific Prevalence of Anaemia, by Country
7.5 Age-specific Prevalence of Kidney Anaemia, by Country
7.6 Treatment Seeking Rate of Anaemia, By Country
8 Anaemia Drugs Market Landscape – 8 Major Markets
8.1 Anaemia Drugs Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Anaemia Drugs Market: Product Landscape
8.2.1 Analysis by Anaemia Type
8.2.2 Analysis by Treatment
9 Clinical Trials and Pipeline Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
9.6 Drug Pipeline Assessment
10 Anaemia Drugs Market Challenges and Unmet Needs
10.1 Treatment Pathway Challenges
10.2 Compliance and Drop-Out Analysis
10.3 Awareness and Prevention Gaps
11 Cost of Treatment
12 Anaemia Drugs Market Dynamics
12.1 Market Drivers and Constraints
12.2 SWOT Analysis
12.2.1 Strengths
12.2.2 Weaknesses
12.2.3 Opportunities
12.2.4 Threats
12.3 PESTEL Analysis
12.3.1 Political
12.3.2 Economic
12.3.3 Social
12.3.4 Technological
12.3.5 Legal
12.3.6 Environment
12.4 Porter’s Five Forces Model
12.4.1 Bargaining Power of Suppliers
12.4.2 Bargaining Power of Buyers
12.4.3 Threat of New Entrants
12.4.4 Threat of Substitutes
12.4.5 Degree of Rivalry
12.5 Key Demand Indicators
12.6 Key Price Indicators
12.7 Industry Events, Initiatives, and Trends
12.8 Value Chain Analysis
13 Anaemia Drugs Market Segmentation (2019-2035) - 8 Major Markets
13.1 Anaemia Drugs Market (2019-2035) by Anaemia Type
13.1.1 Market Overview
13.1.2 Iron Deficiency Anemia
13.1.3 CKD Anemia
13.1.4 Sickle Cell Anemia
13.1.5 Aplastic Anemia
13.1.6 Thalassemia
13.1.7 Others
13.2 Anaemia Drugs Market (2019-2035) by Treatment
13.2.1 Market Overview
13.2.2 Dietary Supplements
13.2.2.1 Iron supplements
13.2.2.2 Vitamin supplements
13.2.2.3 Others
13.2.3 Medicines
13.2.3.1 Antibiotics
13.2.3.2 Hormones (Erythropoietin)
13.2.3.3 Chelation Therapy
13.2.3.4 Others
13.3 Anaemia Drugs Market (2019-2035) by Route of Administration
13.3.1 Market Overview
13.3.2 Oral
13.3.3 Parenteral
13.4 Anaemia Drugs Market (2019-2035) by Distribution Channel
13.4.1 Market Overview
13.4.2 Hospital Pharmacy
13.4.3 Retail Pharmacy
13.4.4 Online Pharmacy
13.5 Anaemia Drugs Market (2019-2035) by Country
13.5.1 Market Overview
13.5.2 United States
13.5.3 United Kingdom
13.5.4 Germany
13.5.5 France
13.5.6 Italy
13.5.7 Spain
13.5.8 Japan
13.5.9 India
14 United States Anaemia Drugs Market (2019-2035)
14.1 United States Anaemia Drugs Market (2019-2035) by Anaemia Type
14.1.1 Market Overview
14.1.2 Iron Deficiency Anemia
14.1.3 CKD Anemia
14.1.4 Sickle Cell Anemia
14.1.5 Aplastic Anemia
14.1.6 Thalassemia
14.1.7 Others
14.2 United States Anaemia Drugs Market (2019-2035) by Treatment
14.2.1 Market Overview
14.2.2 Dietary Supplements
14.2.2.1 Iron supplements
14.2.2.2 Vitamin supplements
14.2.2.3 Others
14.2.3 Medicines
14.2.3.1 Antibiotics
14.2.3.2 Hormones (Erythropoietin)
14.2.3.3 Chelation Therapy
14.2.3.4 Others
14.3 United States Anaemia Drugs Market (2019-2035) by Route of Administration
14.3.1 Market Overview
14.3.2 Oral
14.3.3 Parenteral
14.4 United States Anaemia Drugs Market (2019-2035) by Distribution Channel
14.4.1 Market Overview
14.4.2 Hospital Pharmacy
14.4.3 Retail Pharmacy
14.4.4 Online Pharmacy
15 United Kingdom Anaemia Drugs Market (2019-2035)
15.1 United Kingdom Anaemia Drugs Market (2019-2035) by Anaemia Type
15.1.1 Market Overview
15.1.2 Iron Deficiency Anemia
15.1.3 CKD Anemia
15.1.4 Sickle Cell Anemia
15.1.5 Aplastic Anemia
15.1.6 Thalassemia
15.1.7 Others
15.2 United Kingdom Anaemia Drugs Market (2019-2035) by Treatment
15.2.1 Market Overview
15.2.2 Dietary Supplements
15.2.2.1 Iron supplements
15.2.2.2 Vitamin supplements
15.2.2.3 Others
15.2.3 Medicines
15.2.3.1 Antibiotics
15.2.3.2 Hormones (Erythropoietin)
15.2.3.3 Chelation Therapy
15.2.3.4 Others
15.3 United Kingdom Anaemia Drugs Market (2019-2035) by Route of Administration
15.3.1 Market Overview
15.3.2 Oral
15.3.3 Parenteral
15.4 United Kingdom Anaemia Drugs Market (2019-2035) by Distribution Channel
15.4.1 Market Overview
15.4.2 Hospital Pharmacy
15.4.3 Retail Pharmacy
15.4.4 Online Pharmacy
16 France Anaemia Drugs Market (2019-2035)
16.1 France Anaemia Drugs Market (2019-2035) by Anaemia Type
16.1.1 Market Overview
16.1.2 Iron Deficiency Anemia
16.1.3 CKD Anemia
16.1.4 Sickle Cell Anemia
16.1.5 Aplastic Anemia
16.1.6 Thalassemia
16.1.7 Others
16.2 France Anaemia Drugs Market (2019-2035) by Treatment
16.2.1 Market Overview
16.2.2 Dietary Supplements
16.2.2.1 Iron supplements
16.2.2.2 Vitamin supplements
16.2.2.3 Others
16.2.3 Medicines
16.2.3.1 Antibiotics
16.2.3.2 Hormones (Erythropoietin)
16.2.3.3 Chelation Therapy
16.2.3.4 Others
16.3 France Anaemia Drugs Market (2019-2035) by Route of Administration
16.3.1 Market Overview
16.3.2 Oral
16.3.3 Parenteral
16.4 France Anaemia Drugs Market (2019-2035) by Distribution Channel
16.4.1 Market Overview
16.4.2 Hospital Pharmacy
16.4.3 Retail Pharmacy
16.4.4 Online Pharmacy
17 Italy Anaemia Drugs Market (2019-2035)
17.1 Italy Anaemia Drugs Market (2019-2035) by Anaemia Type
17.1.1 Market Overview
17.1.2 Iron Deficiency Anemia
17.1.3 CKD Anemia
17.1.4 Sickle Cell Anemia
17.1.5 Aplastic Anemia
17.1.6 Thalassemia
17.1.7 Others
17.2 Italy Anaemia Drugs Market (2019-2035) by Treatment
17.2.1 Market Overview
17.2.2 Dietary Supplements
17.2.2.1 Iron supplements
17.2.2.2 Vitamin supplements
17.2.2.3 Others
17.2.3 Medicines
17.2.3.1 Antibiotics
17.2.3.2 Hormones (Erythropoietin)
17.2.3.3 Chelation Therapy
17.2.3.4 Others
17.3 Italy Anaemia Drugs Market (2019-2035) by Route of Administration
17.3.1 Market Overview
17.3.2 Oral
17.3.3 Parenteral
17.4 Italy Anaemia Drugs Market (2019-2035) by Distribution Channel
17.4.1 Market Overview
17.4.2 Hospital Pharmacy
17.4.3 Retail Pharmacy
17.4.4 Online Pharmacy
18 Spain Anaemia Drugs Market (2019-2035)
18.1 Spain Anaemia Drugs Market (2019-2035) by Anaemia Type
18.1.1 Market Overview
18.1.2 Iron Deficiency Anemia
18.1.3 CKD Anemia
18.1.4 Sickle Cell Anemia
18.1.5 Aplastic Anemia
18.1.6 Thalassemia
18.1.7 Others
18.2 Spain Anaemia Drugs Market (2019-2035) by Treatment
18.2.1 Market Overview
18.2.2 Dietary Supplements
18.2.2.1 Iron supplements
18.2.2.2 Vitamin supplements
18.2.2.3 Others
18.2.3 Medicines
18.2.3.1 Antibiotics
18.2.3.2 Hormones (Erythropoietin)
18.2.3.3 Chelation Therapy
18.2.3.4 Others
18.3 Spain Anaemia Drugs Market (2019-2035) by Route of Administration
18.3.1 Market Overview
18.3.2 Oral
18.3.3 Parenteral
18.4 Spain Anaemia Drugs Market (2019-2035) by Distribution Channel
18.4.1 Market Overview
18.4.2 Hospital Pharmacy
18.4.3 Retail Pharmacy
18.4.4 Online Pharmacy
19 Japan Anaemia Drugs Market
19.1 Japan Anaemia Drugs Market (2019-2035) by Anaemia Type
19.1.1 Market Overview
19.1.2 Iron Deficiency Anemia
19.1.3 CKD Anemia
19.1.4 Sickle Cell Anemia
19.1.5 Aplastic Anemia
19.1.6 Thalassemia
19.1.7 Others
19.2 Japan Anaemia Drugs Market (2019-2035) by Treatment
19.2.1 Market Overview
19.2.2 Dietary Supplements
19.2.2.1 Iron supplements
19.2.2.2 Vitamin supplements
19.2.2.3 Others
19.2.3 Medicines
19.2.3.1 Antibiotics
19.2.3.2 Hormones (Erythropoietin)
19.2.3.3 Chelation Therapy
19.2.3.4 Others
19.3 Japan Anaemia Drugs Market (2019-2035) by Route of Administration
19.3.1 Market Overview
19.3.2 Oral
19.3.3 Parenteral
19.4 Japan Anaemia Drugs Market (2019-2035) by Distribution Channel
19.4.1 Market Overview
19.4.2 Hospital Pharmacy
19.4.3 Retail Pharmacy
19.4.4 Online Pharmacy
20 India Anaemia Drugs Market
20.1 India Anaemia Drugs Market (2019-2035) by Anaemia Type
20.1.1 Market Overview
20.1.2 Iron Deficiency Anemia
20.1.3 CKD Anemia
20.1.4 Sickle Cell Anemia
20.1.5 Aplastic Anemia
20.1.6 Thalassemia
20.1.7 Others
20.2 India Anaemia Drugs Market (2019-2035) by Treatment
20.2.1 Market Overview
20.2.2 Dietary Supplements
20.2.2.1 Iron supplements
20.2.2.2 Vitamin supplements
20.2.2.3 Others
20.2.3 Medicines
20.2.3.1 Antibiotics
20.2.3.2 Hormones (Erythropoietin)
20.2.3.3 Chelation Therapy
20.2.3.4 Others
20.3 India Anaemia Drugs Market (2019-2035) by Route of Administration
20.3.1 Market Overview
20.3.2 Oral
20.3.3 Parenteral
20.4 India Anaemia Drugs Market (2019-2035) by Distribution Channel
20.4.1 Market Overview
20.4.2 Hospital Pharmacy
20.4.3 Retail Pharmacy
20.4.4 Online Pharmacy
20.4.5 Others
21 Regulatory Framework
21.1 Regulatory Overview
21.2 US FDA
21.3 EU EMA
21.4 Japan PMDA
21.5 India CDSCO
21.6 Others
22 Patent Analysis
22.1 Analysis by Type of Technology
22.2 Analysis by Publication Year
22.3 Analysis by Issuing Authority
22.4 Analysis by Patent Age
22.5 Analysis by CPC Codes
22.6 Analysis by Patent Valuation
22.7 Analysis by Key Players
23 Grants Analysis
23.1 Analysis by Year
23.2 Analysis by Amount Awarded
23.3 Analysis by Issuing Authority
23.4 Analysis by Grant Application
23.5 Analysis by Funding Institute
23.6 Analysis by NIH Departments
23.7 Analysis by Recipient Organization
24 Funding and Investment Analysis
24.1 Analysis by Funding Instances
24.2 Analysis by Type of Funding
24.3 Analysis by Funding Amount
24.4 Analysis by Leading Players
24.5 Analysis by Leading Investors
24.6 Analysis by Geography
25 Strategic Initiatives
25.1 Analysis by Partnership Instances
25.2 Analysis by Type of Initiatives
25.3 Analysis by Leading Players
25.4 Analysis by Geography
26 Supplier Landscape
26.1 Market Share by Top 5 Companies
26.2 Amgen Inc.
26.2.1 Financial Analysis
26.2.2 Product Portfolio
26.2.3 Demographic Reach and Achievements
26.2.4 Company News and Development
26.2.5 Certifications
26.3 Pieris Pharmaceuticals, Inc.
26.3.1 Financial Analysis
26.3.2 Product Portfolio
26.3.3 Demographic Reach and Achievements
26.3.4 Company News and Development
26.3.5 Certifications
26.4 Pfizer Inc.
26.4.1 Financial Analysis
26.4.2 Product Portfolio
26.4.3 Demographic Reach and Achievements
26.4.4 Company News and Development
26.4.5 Certifications
26.5 Akebia Therapeutics, Inc.
26.5.1 Financial Analysis
26.5.2 Product Portfolio
26.5.3 Demographic Reach and Achievements
26.5.4 Company News and Development
26.5.5 Certifications
26.6 Takeda Pharmaceutical Company Limited
26.6.1 Financial Analysis
26.6.2 Product Portfolio
26.6.3 Demographic Reach and Achievements
26.6.4 Company News and Development
26.6.5 Certifications
27 Key Opinion Leaders (KOL) Insights (Additional Insight)
*The list of players in the competitive landscape section can be customised or made more exhaustive based on your specific requirements.*